The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.
Explainer: How do weight-loss drugs work?
We talk Ozempic, Wegovy and Mounjaro. A number of studies have shown the amazing weight loss potential of a new group of drugs, known to many by their brand names as Ozempic (which is for diabetes), Wegovy and Mounjaro. But how do these new drugs work? How were they discovered and who can use them?
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than-expected fourth-quarter revenues for the drug.
Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the ...
Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025 ...
New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
Some users experience side-effects such as nausea, diarrhoea and fatigue. Other clinical studies have found that some patients taking weight-loss drugs lose muscle at far faster rates than those ...
Whoopi Goldberg warned the public to not believe a "phony" weight loss ad made with artificial intelligence using her ...
A Super Bowl ad touting Hims & Hers Health Inc.’s copycat weight-loss drugs is getting pushback from the branded drugmakers’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback